This webinar describes the use of dextran-based amorphous dispersions in preclinical screening for inhaled dry powders. An overview of particle engineering and amorphous dispersions for inhalation is presented, including conceptual formulation and process guidance, process and scale considerations, materials, and in vitro aerosol performance. Case studies are presented showing the use of these dispersions (1) to deliver a wide range of doses for model toxicology studies, (2) to determine feasibility for a water-insoluble API, and (3) to enable rapid formulation of a peptide for inhalation.